Aggressive variant prostate cancers (AVPCs) are characterized by distinct clinical features like rapid tumor growth, presence of visceral and lytic bone metastasis, prostate-specific membrane antigen (PSMA)-low and fluorodeoxyglucose (FDG)-high uptake on PET scan, limited response to androgen deprivation therapy and neuroendocrine differentiation [9,13]. This evidence concerns the gene FOLH1 and prostate carcinoma.